Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -1.00 (-3.96%)
Spread: 0.50 (2.083%)
Open: 25.25
High: 25.25
Low: 24.25
Prev. Close: 25.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: ING Real, Intellego, Oxford Intruments...

Wed, 20th Jan 2010 13:10

ING UK Real Estate Income Trust will repay £15m of debt through the purchase and cancellation of loan notes at a discount to nominal value in two separate transactions.The transaction will result in a one off gain to NAV expected to be in the order of £680,000, and will also save over £719,000 per annum in interest charges."This is an opportunistic purchase, enabling us to enhance both the underlying NAV and income account, whilst de-risking the overall portfolio by maintaining the current LTV ratio and improving the interest cover position, fund manager Michael Morris said.Angus Forrest, training and e-learning group Intellego's chairman, says the firm has won a material order with a leading retail specialist to provide productivity improvement services for the next 12 months. Order intake in the third quarter of the year ending 31 March 2010 was £898,000.Oxford Instruments performance from October to January was in line with the board's expectations and above the same period in the prior year, aided by the effects of the restructuring programme implemented last year and favourable currency movements. Research markets remain robust. The tentative signs of improvement in Industrial markets continue, albeit from a low level and visibility remains limited, it added.Lower than expected endoscopy sales and higher field costs will mean Puricore's earnings this year missing targets, though it says the miss will not be significant. Fourth quarter sales in 2009 were $10.4m, up 75%, while revenue for the year was about $40m, up 19%. "In 2010, the company anticipates cash flow profitability in PuriCore's Endoscopy business in the UK and continued significant progress in the Food Safety business in both the US and Canada," it said. Cake and bread maker Finsbury Food Group has appointed Stephen Boyd as its new finance boss and confirmed it continues to trade in line with market expectations.The 47-year-old, who has experience at WT Foods, Noon Products and Golden Wonder, replaces Lisa Morgan who'll leave the company by the end of March 2010.Renewable fuels company GTL Resources had a record December, with subsidiary Illinois River Energy selling 9.8 million gallons of ethanol and 24.2 thousand tons of dried distillers grains with solubles.'With the recent commodity margin rally in the ethanol industry coupled with GTL's strong operational performance since September 2009, the group expects to report improved results in the second half,' said the firm.Asset finance company 1pm said trading has been in line with management expectations since its last trading update in October. Revenue in the 6 months to 30 November 2009 edged higher to £0.68m from £0.66m the year before, but the loss before tax widened to £0.23m from £0.01m.Bad debt write-offs in the period were £95,000, while general bad debt provisions of £120,000 were accrued as a result of a number of customers going bankrupt during the reporting period.Brulines, which provides monitoring systems and data management services for the UK leisure sector, has won a contract to supply vending telemetry hardware over a period of three years to an unnamed international consumer goods company.Chinese specialist engineering company China Wonder has taken a £0.2m loan from Wonder Employees Capital Limited (WECL), a company wholly owned by Qingjie Zhao, a substantial shareholder.The loan accrues interest at a rate of 5% per annum. The loan agreement gives WECL the right to convert the loan into ordinary shares in the capital of China Wonder at a price of 10p per share. Scientists at the Institute of Cancer Research and Sareum have developed a chemical compounds that increase the effectiveness of current cancer therapeutics.Media services business Dawson Holdings is on the look-out for a new finance director after the current position holder, Adrian Wood, announced his intention to retire from the role on 31 March. Wood will stay on as company secretary until the end of June.
More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.